Labopharm appoints Jeffrey M. Dayno, M.D. as Chief Medical Officer
Labopharm Inc. announced the appointment of Jeffrey M. Dayno, M.D. as Chief Medical Officer. Dr. Dayno will be responsible for leading the clinical activities for Labopharm's drug development programs, as well as overseeing the Company's medical affairs functions, including medical information and pharmacovigilance, for all commercialized products. Dr. Dayno will be based out of Labopharm's U.S. office in Princeton, New Jersey.
Dr. Dayno joins Labopharm from Cephalon, Inc., where he was Vice President, Medical Services overseeing a team of Medical Directors in support of commercial franchises. Prior to his tenure at Cephalon, Dr. Dayno spent seven years with Merck & Co., Inc. in increasingly senior Medical Services positions, culminating in his role as Senior Director, Medical Services, U.S. Medical & Scientific Affairs. In addition, Dr. Dayno has held a number of clinical appointments, including Clinical Assistant Professor of Neurology, Jefferson Medical College (Philadelphia) and Medical Director Jefferson Health Systems Stroke Center Network (Philadelphia).
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
rbr Computertechnik GmbH - Iserlohn, Germany
A new target for immuno-oncology therapies
QIAGEN Instruments AG - Hombrechtikon, Switzerland
Protein Associated with Parkinson’s Travels from Brain to Gut - A new laboratory study provides clues on a particular pathway of “alpha-synuclein” diffusion
BIOCRATES expands management board: New Chief Technology Officer (CTO) Dr. Ralph Zahn
New 'suicide' molecule halts rheumatoid arthritis - Researcher invents nontoxic drug that forces hyperactive immune cells to die
Crucell's Supervisory Board Nominates Mr. W. Burns, Mr. J. Shannon and Mr. G. Siber as New Board Members
Cytotoxic therapies to feel sting of generics
